Will TrovaGene Be an "ASCO Effect" Beneficiary?

Shares of TrovaGene Inc. (Nasdaq: TROV) surged more than 9% Friday and as much as 13.5% Monday after the Liquid Biopsy biotech company announced that a TrovaGene scientist presented clinical research findings at a prestigious cancer-treatment symposium in Florida.

With biotechs, these presentations can have an outsized impact on a company's share price.

  1. ulhas | May 19, 2016

    simply amazing predictions.

    • (Admin) Bill Patalon | May 20, 2016

      Dear Ulhas:

      Thanks for the kind words … and for taking the time to offer them.

      We've followed this opportunity closely.

      And we'll continue to do so.

      Thank you again. And I mean that.

      Respectfully yours;

      William Patalon III
      Editorial Director/Executive Editor
      Money Map Press LLC

Leave a Reply

Your email address will not be published. Required fields are marked *

Some HTML is OK